The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...

GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National ...

London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

The FTSE 100 is expected to open flat on Friday, having closed up 1.1% on Thursday at 8,260.09.

GSK's Nucala approved in China for CRSwNP, affecting 1/3 of 107 million sinusitis patients; third IL-5 condition indication in the region. Phase 3 trial shows Nucala reduces COPD exacerbations ...